Dhampur Bio Organics enters mycoprotein business

Dhampur Bio Organics will enter the mycoprotein business, using sugar and molasses as feedstock to manufacture the alternative protein, according to ChiniMandi. The Dhampur Bio Organics foray makes the sugar major one of the first traditional sugar companies to bet on fermentation-derived protein, and the Dhampur Bio Organics move targets demand for sustainable food ingredients.

Mycoprotein is produced by fermenting fungi into a high-protein ingredient for meat alternatives. Mycoprotein in India is still a nascent market, which gives early movers the chance to shape supply chains and customer relationships from the ground up.

The company's edge is its raw material. Sugar feedstock protein production turns low-margin cane by-products into high-value ingredients, improving realisations from every tonne of cane crushed and leveraging existing handling infrastructure.

Dhampur Bio Organics: why mycoprotein, why now

The Dhampur Bio Organics bet rests on the global search for alternative protein and India's need to add value to its sugar economy. Fermentation-derived ingredients are in demand from food manufacturers seeking reliable, traceable supply.

This bio-organics expansion into fermentation positions the company at the intersection of food technology and agri-processing. Investors have been warming to both sectors, and an integrated Indian producer could compete on cost and traceability.

There are execution risks. Mycoprotein in India faces limited domestic demand and an evolving regulatory landscape, so the company will likely target export markets and ingredient buyers first, building scale before any consumer-facing products.

Dhampur Bio Organics joins the alternative-protein race

The Dhampur Bio Organics entry adds an Indian heavyweight to a race dominated by startups and Western ingredient firms. If sugar feedstock protein economics prove out at scale, peers in India's sugar industry are likely to follow the template.

With sugar surpluses recurring and ethanol blending absorbing only part of output, diversification into bio-based products offers steadier earnings. The bio-organics expansion is a strategic answer to that structural challenge, and alternative protein is its flagship.

Fermentation-derived proteins are attracting capital worldwide as food companies hunt for sustainable ingredients. Mycoprotein's advantage is familiarity: unlike newer precision-fermentation products, it has been sold to consumers for decades, which smooths regulatory approval and consumer acceptance in new markets.

India's sugar industry, meanwhile, is under structural pressure to diversify. Ethanol blending has absorbed part of the surplus, but mills still face cyclical swings in sugar prices. Bio-based products, from biochemicals to proteins, offer a way to sweat cane assets harder and stabilise earnings.

ChiniMandi's reporting positions Dhampur among the first movers in the country's sugar sector to attempt the leap. Competitors will watch the capital expenditure, technology partnership and offtake arrangements closely before deciding whether to follow suit.

Technology licensing is likely to be central to the plan. Few sugar companies possess fermentation expertise in-house, so a partnership with a technology provider or an acquisition of know-how would be the fastest route to production. The choice of partner will say much about the project's ambition.

If the venture succeeds, it could redefine how the market values sugar companies, shifting the lens from commodity cycles to bio-economy optionality.

Investment figures and timelines were not disclosed. But the Dhampur Bio Organics direction is clear: convert the cane platform into a broader bio-economy business, with mycoprotein as the flagship venture.

Mycoprotein production relies on fermentation rather than farmland, a route analysts often describe as land-efficient, though scaling it profitably remains the industry's central challenge.